{"document": {"publication": "Tag My News", "full_text": "takeda pharmaceutical co , japan's largest drugmaker, is buying privately held swiss rival nycomed for $13.6 billion, giving it access to a newly approved lung-disease drug, which is expected to be a major source of revenue growth.", "title": "takeda to buy swiss drugmaker nycomed for $13.6 billion", "line_count": 1, "filename": "29081", "publication_date": "19-05-2011 12:05:14", "lines_and_colors": [["takeda pharmaceutical co , japan's largest drugmaker, is buying privately held swiss rival nycomed for $13.6 billion, giving it access to a newly approved lung-disease drug, which is expected to be a major source of revenue growth.", {}]]}}